Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary, Hainan General Sanyou Pharmaceutical Co., Ltd. (referred to as "Sanyou Pharmaceutical"), has received the drug registration certificate for Nicergoline Tablets from the National Medical Products Administration [1] Group 1 - Nicergoline Tablets are primarily used to improve motivation deficits caused by sequelae of cerebral infarction [1] - The drug is also applicable for vascular dementia, particularly in early treatment, where it can enhance cognitive and memory functions and reduce the severity of the disease [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Valsartan capsules, which will enhance its cardiovascular product portfolio and overall competitiveness [1] Group 1: Product Approval - The company announced that it has obtained the drug registration certificate for Valsartan capsules, a prescription medication classified as a chemical drug of category 4, with a specification of 80mg [1] - The approval is significant as it allows the company to offer a treatment for mild to moderate primary hypertension [1] Group 2: Market Impact - The registration certificate for Valsartan capsules was granted in December 2025, indicating a future opportunity for the company to expand its product offerings [1] - The sales of the drug may be influenced by various factors such as domestic pharmaceutical policy changes, tender procurement, and market environment fluctuations, which introduces a level of uncertainty [1]

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received the drug registration certificate for Naloxone Hydrochloride Injection from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product line [1] Group 1: Product Approval - The approval is for Naloxone Hydrochloride Injection, which is indicated for multiple uses including reversing respiratory depression caused by opioid drugs during anesthesia recovery [1] - The product can also be used to partially or completely reverse respiratory depression due to opioid overdose, rescue acute ethanol poisoning, and diagnose acute opioid overdose [1]

Core Viewpoint - Kyushu Tong (600998.SH) announced that its subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received approval from the National Medical Products Administration for the drug registration certificate of Isopropamide Iodide Injection, indicating a significant development in its product portfolio [1] Group 1 - The approved drug, Isopropamide Iodide Injection, is an antihistamine used for treating skin and mucosal allergies, motion sickness, and as an adjunct treatment before and after anesthesia and surgery [1] - The drug also serves to prevent and treat radiation sickness or drug-induced nausea and vomiting, highlighting its therapeutic versatility [1]

Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) has received the Drug Registration Certificate for Brexpiprazole Tablets from the National Medical Products Administration, indicating regulatory approval for the treatment of schizophrenia [1] Group 1 - The Drug Registration Certificate numbers are 2025S03922 and 2025S03923 [1] - Brexpiprazole's mechanism of action in treating schizophrenia is not fully understood, but it may involve partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, along with antagonist activity at serotonin 5-HT2A receptors [1]

重酒石酸去甲肾上腺素注射液用于急性低血压状态的血压恢复;也可用于心跳骤停的辅助治疗和心跳骤 停复苏后的血压维持。对血容量不足导致的休克，本品作为急救时补充血容量的辅助治疗，以使血压回 升，暂时维持脑与冠状动脉灌注，直到补充血容量治疗发生作用。公司重酒石酸去甲肾上腺素注射液按 新注册分类化学药品3类获得药品注册证书，视同通过一致性评价。 华纳药厂(688799.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的重酒石酸去甲肾上腺 素注射液《药品注册证书》。 ...

Core Viewpoint - The company TianKang (301263.SZ) announced that its wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd. (referred to as "Huabo Kaisheng"), has received a drug registration certificate from the National Medical Products Administration for Finasteride and Tadalafil Capsules, making it the first company in China to obtain this certification for this drug combination [1]. Group 1 - Huabo Kaisheng is the first company in China to receive a drug registration certificate for Finasteride and Tadalafil Capsules [1]. - The drug is a combination of Finasteride, a 5α-reductase inhibitor, and Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, specifically designed to treat symptoms of benign prostatic hyperplasia (BPH) [1]. - The combination of these two drugs provides a synergistic therapeutic effect, with Finasteride reducing prostate volume and alleviating urinary difficulties, while Tadalafil directly relieves lower urinary tract symptoms associated with BPH [1]. Group 2 - Tadalafil also has the added benefit of improving erectile function, addressing potential erectile dysfunction side effects that may arise from Finasteride treatment [1].

Core Viewpoint - The company has received approval for the registration certificate of Clomipramine Hydrochloride Tablets, which is used for the treatment of depression, enhancing its product line and market competitiveness [1] Group 1 - The subsidiary, Ningbo Tianheng Pharmaceutical Co., Ltd., has been granted the drug registration certificate by the National Medical Products Administration [1] - The approval of Clomipramine Hydrochloride Tablets will further enrich the subsidiary's product offerings [1] - The production and sales of the new product may be influenced by industry policies and market environment changes, leading to uncertainties regarding its impact on the company's performance [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration certificate of levofloxacin oral solution, indicating a significant advancement in its product portfolio [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted the drug registration certificate for levofloxacin oral solution [1] - Levofloxacin is classified as a third-generation fluoroquinolone antibiotic, which works by inhibiting bacterial DNA gyrase activity, thereby obstructing bacterial DNA replication [1] Group 2: Product Characteristics - Levofloxacin exhibits a broad antibacterial spectrum and strong antibacterial action, making it a valuable addition to the company's offerings [1]

Core Viewpoint - The company has received approval for the registration of Levofloxacin oral solution from the National Medical Products Administration, indicating a significant advancement in its product portfolio [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted the drug registration certificate for Levofloxacin oral solution [1] - Levofloxacin is classified as a third-generation fluoroquinolone antibiotic, which works by inhibiting bacterial DNA gyrase activity, thereby blocking bacterial DNA replication [1] Group 2: Product Characteristics - Levofloxacin exhibits a broad antibacterial spectrum and strong antibacterial action, making it a valuable addition to the company's offerings [1]